New biotechnology combines targeted and immune therapies to kill treatment-resistant cancer cells

byNYU Langone HealthBinding profiles soto-p7/A03 (top row) and p7WT/A03 (bottom row) of clone R011 (left column), the naïve deep mutational scanning library (middle column), and the pool after s

Updated on: January 12,2024

New biotechnology combines targeted and immune therapies to kill treatment-resistant cancer cells

byNYU Langone HealthBinding profiles soto-p7/A03 (top row) and p7WT/A03 (bottom row) of clone R011 (left column), the naïve deep mutational scanning library (middle column), and the pool after s

Updated on:January 12,2024

New treatment approach shows promise in hard-to-treat pediatric cancers

byFlorida International UniversityResearcher Diana Azzam and Logan Jenner, a participant in her clinical study, in the Azzam Lab at Florida International University. Credit: Florida Internationa

Updated on: April 28,2024

New treatment approach shows promise in hard-to-treat pediatric cancers

byFlorida International UniversityResearcher Diana Azzam and Logan Jenner, a participant in her clinical study, in the Azzam Lab at Florida International University. Credit: Florida Internationa

Updated on:April 28,2024

Modest rise in UK cancer cases but substantial decline in deaths over last 25 years: Study

by British Medical JournalCredit: Unsplash/CC0 Public DomainCases of cancer among UK men and women aged 35-69 years have seen a modest rise over the last quarter of a century, but there has also

Updated on: March 20,2024

Modest rise in UK cancer cases but substantial decline in deaths over last 25 years: Study

by British Medical JournalCredit: Unsplash/CC0 Public DomainCases of cancer among UK men and women aged 35-69 years have seen a modest rise over the last quarter of a century, but there has also

Updated on:March 20,2024

New cancer immunotherapy approach turns human cells into tiny anti-tumor drug factories

by University of California - San DiegoUC San Diego School of Medicine researchers developed a method to use B cells to manufacture and secrete microRNA-containing vesicles and showed they can in

Updated on: March 12,2024

New cancer immunotherapy approach turns human cells into tiny anti-tumor drug factories

by University of California - San DiegoUC San Diego School of Medicine researchers developed a method to use B cells to manufacture and secrete microRNA-containing vesicles and showed they can in

Updated on:March 12,2024

Researchers demonstrate that a machine learning model predicts oxaliplatin benefit

by NRG OncologyCredit: Unsplash/CC0 Public DomainThe current standard of care for treating patients with stage 3 colon cancer is to use adjuvant therapy with FOLFOX, a combination of the drugs fluorou

Updated on: May 16,2024

Researchers demonstrate that a machine learning model predicts oxaliplatin benefit

by NRG OncologyCredit: Unsplash/CC0 Public DomainThe current standard of care for treating patients with stage 3 colon cancer is to use adjuvant therapy with FOLFOX, a combination of the drugs fluorou

Updated on:May 16,2024

Oral sex is now the leading risk factor for throat cancer, says researcher

by Hisham Mehanna,The ConversationThe oropharynx is middle section of the throat (pharynx). Credit:Scientific Animations/Wikimedia Commons,CC BY-SAOver the past two decades, there ha

Updated on: January 30,2024

Oral sex is now the leading risk factor for throat cancer, says researcher

by Hisham Mehanna,The ConversationThe oropharynx is middle section of the throat (pharynx). Credit:Scientific Animations/Wikimedia Commons,CC BY-SAOver the past two decades, there ha

Updated on:January 30,2024

The inaugural Sony-Nature Tech Women Award announced, with four winners

Updated on: February 17,2025

The inaugural Sony-Nature Tech Women Award announced, with four winners

Updated on:February 17,2025

Tumor cells' response to chemotherapy is driven by randomness, shows study

byGarvan Institute of Medical ResearchNeuroblastoma cells (cyan) growing as a tumour and the surrounding collagen matrix (magenta). The cells are expressing a biosensor (JNK-KTR) that reads out

Updated on: January 23,2024

Tumor cells' response to chemotherapy is driven by randomness, shows study

byGarvan Institute of Medical ResearchNeuroblastoma cells (cyan) growing as a tumour and the surrounding collagen matrix (magenta). The cells are expressing a biosensor (JNK-KTR) that reads out

Updated on:January 23,2024

New research may hold key to better treatments for aggressive brain cancer

by Spectrum HealthPrakash Chinnaiyan, M.D., a physician scientist in the Department of Radiation Oncology at Corewell Health in Southeast, Mich. Credit: Elizabeth Debeliso, Corewell HealthFor decades,

Updated on: January 13,2024

New research may hold key to better treatments for aggressive brain cancer

by Spectrum HealthPrakash Chinnaiyan, M.D., a physician scientist in the Department of Radiation Oncology at Corewell Health in Southeast, Mich. Credit: Elizabeth Debeliso, Corewell HealthFor decades,

Updated on:January 13,2024

Cancer survivors see mostly positives in how they have changed

by Jeff Grabmeier,The Ohio State UniversityCredit: CC0 Public DomainTwo years after diagnosis, breast cancer survivors have four times more positive than negative thoughts about changes they exp

Updated on: March 12,2024

Cancer survivors see mostly positives in how they have changed

by Jeff Grabmeier,The Ohio State UniversityCredit: CC0 Public DomainTwo years after diagnosis, breast cancer survivors have four times more positive than negative thoughts about changes they exp

Updated on:March 12,2024

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study

by Impact Journals LLCTAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling. Credit: 2024 Zhang et al.A new research paper waspublishedinOncotargettitled,

Updated on: July 10,2024

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study

by Impact Journals LLCTAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling. Credit: 2024 Zhang et al.A new research paper waspublishedinOncotargettitled,

Updated on:July 10,2024

How a little-known glycoprotein blocks a cancer cell's immune response

by University of MichiganThe interaction between STC1 and calreticulin. Credit: University of Michigan Rogel Cancer CenterIt was an unexpected discovery that started with an analysis of more than

Updated on: March 26,2024

How a little-known glycoprotein blocks a cancer cell's immune response

by University of MichiganThe interaction between STC1 and calreticulin. Credit: University of Michigan Rogel Cancer CenterIt was an unexpected discovery that started with an analysis of more than

Updated on:March 26,2024